TDMS Study 05180-07 Pathology Tables
NTP STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS REPORT: PEIRPT10
LAB: Battelle Northwest GALLIUM ARSENIDE DATE: 03/09/99
EXPERIMENT: 05180 TEST: 07 TIME: 14:29:27
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: NO1-ES-25335 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 62033B
PATHOLOGIST: MILLER, RODNEY CAS: 1303-00-0000
------------------------------------------------------------------------------------------------------------------------------------
2 YEAR CHRONIC MICE
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS REPORT: PEIRPT10
LAB: Battelle Northwest GALLIUM ARSENIDE DATE: 03/09/99
EXPERIMENT: 05180 TEST: 07 TIME: 14:29:27
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-25335 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 62033B
PATHOLOGIST: MILLER, RODNEY CAS: 1303-00-0000
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF GALLIUM ARSENIDE
===============================================================
Male Mice
------------
Organ Morphology
----- ----------
Adrenal Cortex Hypertrophy
Harderian Gland Hyperplasia
Heart Cardiomyopathy
Larynx: Squamous Epithelium Hyperplasia
Liver Eosinophilic Focus
Lung Infiltration Cellular Histiocyte
Inflammation Chronic Focal
Inflammation Focal
Lung: Alveolar Epithelium Hyperplasia
Lung: Alveolus Foreign Body
Proteinosis
Lymph Node, Bronchial Hyperplasia
Mesentery: Fat Necrosis
Preputial Gland Inflammation
Testes Atrophy
===============================================================
Female Mice
------------
Organ Morphology
----- ----------
Kidney Nephropathy
Liver Eosinophilic Focus
Lung Infiltration Cellular Histiocyte
Inflammation Chronic Focal
Inflammation Focal
Lung: Alveolar Epithelium Hyperplasia
Lung: Alveolus Foreign Body
Proteinosis
Lymph Node, Bronchial Hyperplasia
Mesentery: Fat Necrosis
Nose: Olfactory Epithelium Degeneration Hyaline
Pituitary Gland: Pars Distalis Hyperplasia
Spleen Hematopoietic Cell Proliferation
Hyperplasia Lymphoid
===============================================================
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 1
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 10/50 (20%) 7/50 (14%) 4/48 (8%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/49 (0%) |
|POLY-3 ADJUSTED (b)| 9.1% 21.6% 16.3% 9.0% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 3/35 (9%) 8/38 (21%) 7/34 (21%) 3/34 (9%) |0/36 (0%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | 647 609 733 (T) 723 |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.293N P=0.105 P=0.240 P=0.634 |(e) (e) (e) (e) |
|POLY 3 | P=0.251N P=0.086 P=0.243 P=0.642N |(e) (e) (e) (e) |
|POLY 1.5 | P=0.254N P=0.083 P=0.253 P=0.640 |(e) (e) (e) (e) |
|POLY 6 | P=0.253N P=0.090 P=0.232 P=0.641N |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.261N P=0.087 P=0.237 P=0.638N |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.274N P=0.074 P=0.262 P=0.619 |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Hypertrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 38/50 (76%) 33/50 (66%) 38/50 (76%) 30/48 (63%) |5/50 (10%) 5/50 (10%) 7/50 (14%) 7/49 (14%) |
|POLY-3 ADJUSTED (b)| 82.7% 71.1% 82.9% 65.0% |11.2% 11.0% 17.1% 16.8% |
|TERMINAL (d) | 33/35 (94%) 29/38 (76%) 30/34 (88%) 25/34 (74%) |5/36 (14%) 5/34 (15%) 6/31 (19%) 5/29 (17%) |
|FIRST INCIDENCE | 462 659 504 501 |735 (T) 735 (T) 629 646 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.255N P=0.053N P=0.490 P=0.077N |P=0.144 P=0.596 P=0.277 P=0.249 |
|POLY 3 | P=0.079N P=0.128N P=0.606 P=0.037N* |P=0.202 P=0.624N P=0.316 P=0.328 |
|POLY 1.5 | P=0.107N P=0.137N P=0.608 P=0.051N |P=0.221 P=0.629N P=0.336 P=0.343 |
|POLY 6 | P=0.058N P=0.112N P=0.626 P=0.025N* |P=0.185 P=0.620N P=0.301 P=0.313 |
|LOGISTIC REGRESSION| P=0.120N P=0.079N P=0.540 P=0.051N |P=0.171 P=0.596 P=0.286 P=0.297 |
|COCH-ARM / FISHERS | P=0.190N P=0.189N P=0.592N P=0.109N |P=0.249 P=0.630N P=0.380 P=0.365 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 2
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 1/47 (2%) |1/50 (2%) 2/49 (4%) 1/50 (2%) 2/49 (4%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 2.3% |2.2% 4.5% 2.4% 4.8% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 0/34 (0%) 1/34 (3%) |1/36 (3%) 2/34 (6%) 0/31 (0%) 2/29 (7%) |
|FIRST INCIDENCE | --- --- --- 733 (T) |735 (T) 735 (T) 659 735 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.178 (e) (e) P=0.494 |P=0.403 P=0.480 P=0.726 P=0.424 |
|POLY 3 | P=0.182 (e) (e) P=0.498 |P=0.444 P=0.496 P=0.740 P=0.471 |
|POLY 1.5 | P=0.181 (e) (e) P=0.496 |P=0.457 P=0.494 P=0.746 P=0.480 |
|POLY 6 | P=0.183 (e) (e) P=0.501 |P=0.431 P=0.499 P=0.734 P=0.462 |
|LOGISTIC REGRESSION| (e) (e) (e) P=0.494 |P=0.433 P=0.480 P=0.755 P=0.424 |
|COCH-ARM / FISHERS | P=0.178 (e) (e) P=0.485 |P=0.475 P=0.492 P=0.753N P=0.492 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Bone |
| Fibrous Osteodystrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/49 (2%) 2/50 (4%) 2/50 (4%) 0/50 (0%) |21/50 (42%) 24/50 (48%) 14/50 (28%) 18/50 (36%) |
|POLY-3 ADJUSTED (b)| 2.3% 4.4% 4.7% 0.0% |44.8% 52.2% 34.0% 42.1% |
|TERMINAL (d) | 1/34 (3%) 2/38 (5%) 2/34 (6%) 0/34 (0%) |16/36 (44%) 20/34 (59%) 11/31 (36%) 16/29 (55%) |
|FIRST INCIDENCE | 733 (T) 733 (T) 733 (T) --- |237 659 560 529 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.278N P=0.539 P=0.500 P=0.500N |P=0.374N P=0.285 P=0.235N P=0.513 |
|POLY 3 | P=0.256N P=0.524 P=0.501 P=0.490N |P=0.220N P=0.307 P=0.204N P=0.481N |
|POLY 1.5 | P=0.256N P=0.519 P=0.504 P=0.491N |P=0.174N P=0.307 P=0.167N P=0.425N |
|POLY 6 | P=0.258N P=0.529 P=0.496 P=0.490N |P=0.279N P=0.308 P=0.241N P=0.544N |
|LOGISTIC REGRESSION| P=0.278N P=0.539 P=0.500 (e) |P=0.207N P=0.346 P=0.152N P=0.401N |
|COCH-ARM / FISHERS | P=0.260N P=0.508 P=0.508 P=0.495N |P=0.122N P=0.344 P=0.104N P=0.341N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 3
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Bone Marrow |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/49 (4%) 3/50 (6%) 2/50 (4%) 3/48 (6%) |2/50 (4%) 1/50 (2%) 2/50 (4%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 4.5% 6.5% 4.6% 6.7% |4.4% 2.2% 4.8% 2.4% |
|TERMINAL (d) | 0/34 (0%) 2/38 (5%) 1/34 (3%) 0/34 (0%) |0/36 (0%) 1/34 (3%) 1/31 (3%) 0/29 (0%) |
|FIRST INCIDENCE | 462 729 639 555 |439 735 (T) 421 710 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.473 P=0.533 P=0.686 P=0.506 |P=0.531N P=0.518N P=0.649 P=0.542N |
|POLY 3 | P=0.481 P=0.517 P=0.687 P=0.507 |P=0.512N P=0.503N P=0.658 P=0.527N |
|POLY 1.5 | P=0.480 P=0.517 P=0.693 P=0.504 |P=0.498N P=0.503N P=0.670 P=0.516N |
|POLY 6 | P=0.482 P=0.519 P=0.680 P=0.509 |P=0.526N P=0.502N P=0.648 P=0.539N |
|LOGISTIC REGRESSION| P=0.432 P=0.447 P=0.690 P=0.355 |P=0.455N P=0.486N P=0.605N P=0.476N |
|COCH-ARM / FISHERS | P=0.470 P=0.510 P=0.684N P=0.490 |P=0.479N P=0.500N P=0.691N P=0.500N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Brain: Meninges |
| Infiltration Cellular Mononuclear Cell |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 1/50 (2%) 0/49 (0%) |2/50 (4%) 5/50 (10%) 3/50 (6%) 3/50 (6%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 2.3% 0.0% |4.5% 11.0% 7.3% 7.1% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 1/34 (3%) 0/34 (0%) |2/36 (6%) 4/34 (12%) 2/31 (7%) 2/29 (7%) |
|FIRST INCIDENCE | --- --- 733 (T) --- |735 (T) 715 659 714 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.638 (e) P=0.494 (e) |P=0.516 P=0.200 P=0.432 P=0.409 |
|POLY 3 | P=0.657 (e) P=0.496 (e) |P=0.560N P=0.221 P=0.458 P=0.472 |
|POLY 1.5 | P=0.655 (e) P=0.498 (e) |P=0.541N P=0.218 P=0.471 P=0.484 |
|POLY 6 | P=0.658 (e) P=0.493 (e) |P=0.561 P=0.224 P=0.447 P=0.459 |
|LOGISTIC REGRESSION| (e) (e) P=0.494 (e) |P=0.556 P=0.213 P=0.448 P=0.440 |
|COCH-ARM / FISHERS | P=0.646 (e) P=0.500 (e) |P=0.515N P=0.218 P=0.500 P=0.500 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 4
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Epididymis |
| Granuloma Sperm |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 0/50 (0%) 1/49 (2%) | |
|POLY-3 ADJUSTED (b)| 0.0% 4.4% 0.0% 2.2% | |
|TERMINAL (d) | 0/35 (0%) 2/38 (5%) 0/34 (0%) 1/34 (3%) | |
|FIRST INCIDENCE | --- 733 (T) --- 733 (T) | |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.626 P=0.257 (e) P=0.494 | |
|POLY 3 | P=0.644N P=0.247 (e) P=0.504 | |
|POLY 1.5 | P=0.644N P=0.245 (e) P=0.503 | |
|POLY 6 | P=0.644N P=0.251 (e) P=0.505 | |
|LOGISTIC REGRESSION| (e) P=0.257 (e) P=0.494 | |
|COCH-ARM / FISHERS | P=0.640 P=0.247 (e) P=0.495 | |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Epididymis |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 1/50 (2%) 0/50 (0%) 0/49 (0%) | |
|POLY-3 ADJUSTED (b)| 4.5% 2.2% 0.0% 0.0% | |
|TERMINAL (d) | 1/35 (3%) 1/38 (3%) 0/34 (0%) 0/34 (0%) | |
|FIRST INCIDENCE | 462 733 (T) --- --- | |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.111N P=0.476N P=0.243N P=0.241N | |
|POLY 3 | P=0.109N P=0.490N P=0.246N P=0.236N | |
|POLY 1.5 | P=0.108N P=0.492N P=0.242N P=0.237N | |
|POLY 6 | P=0.111N P=0.487N P=0.250N P=0.237N | |
|LOGISTIC REGRESSION| P=0.113N P=0.548N P=0.245N P=0.298N | |
|COCH-ARM / FISHERS | P=0.106N P=0.500N P=0.247N P=0.253N | |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 5
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Eye |
| Degeneration |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/2 (0%) 1/1 (100%) 0/0 (0%) 2/4 (50%) |0/1 (0%) 0/0 (0%) 1/2 (50%) 0/1 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 100.0% 0.0% 50.2% |0.0% 0.0% 50.0% 0.0% |
|TERMINAL (d) | 0/2 (0%) 0/0 (0%) 0/0 (0%) 2/3 (67%) |0/0 (0%) 0/0 (0%) 1/2 (50%) 0/1 (0%) |
|FIRST INCIDENCE | --- 609 --- 733 (T) |--- --- 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.360 P=0.527 (e) P=0.309 |P=0.638N (e) P=1.000 (e) |
|POLY 3 | (e) P=1.000 (e) P=0.385 |(e) (e) P=0.677 (e) |
|POLY 1.5 | (e) P=1.000 (e) P=0.386 |(e) (e) P=0.649 (e) |
|POLY 6 | (e) P=1.000 (e) P=0.383 |(e) (e) P=0.714 (e) |
|LOGISTIC REGRESSION| P=0.233 (e) (e) P=0.309 |(e) (e) P=1.000 (e) |
|COCH-ARM / FISHERS | P=0.441 P=0.333 (e) P=0.400 |P=0.793 (e) P=0.667 (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Harderian Gland |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/47 (2%) 1/48 (2%) 10/49 (20%) 1/48 (2%) |0/5 (0%) 0/4 (0%) 0/3 (0%) 0/2 (0%) |
|POLY-3 ADJUSTED (b)| 2.3% 2.3% 23.3% 2.3% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/35 (0%) 1/37 (3%) 9/34 (27%) 1/33 (3%) |0/3 (0%) 0/3 (0%) 0/2 (0%) 0/2 (0%) |
|FIRST INCIDENCE | 699 733 (T) 729 733 (T) |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.276 P=0.746N P=0.005 ** P=0.754 |(e) (e) (e) (e) |
|POLY 3 | P=0.312 P=0.755N P=0.004 ** P=0.758N |(e) (e) (e) (e) |
|POLY 1.5 | P=0.317 P=0.756N P=0.004 ** P=0.757N |(e) (e) (e) (e) |
|POLY 6 | P=0.302 P=0.754N P=0.003 ** P=0.760N |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.297 P=0.757N P=0.004 ** P=0.759N |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.326 P=0.747N P=0.005 ** P=0.747N |(e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 6
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Heart |
| Cardiomyopathy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 48/50 (96%) 50/50 (100%) 49/50 (98%) 47/50 (94%) |49/50 (98%) 48/50 (96%) 47/50 (94%) 47/50 (94%) |
|POLY-3 ADJUSTED (b)| 99.5% 100.0% 98.0% 95.2% |99.9% 97.9% 97.0% 97.6% |
|TERMINAL (d) | 35/35 (100%) 38/38 (100%) 33/34 (97%) 33/34 (97%) |36/36 (100%) 33/34 (97%) 30/31 (97%) 29/29 (100%) |
|FIRST INCIDENCE | 457 473 232 406 |439 302 281 412 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.464 P=0.424N P=0.402 P=0.548N |P=0.110 P=0.529 P=0.254 P=0.160 |
|POLY 3 | P=0.044N* P=0.998 P=0.604N P=0.223N |P=0.327N P=0.511N P=0.339N P=0.430N |
|POLY 1.5 | P=0.050N P=0.826 P=0.686N P=0.251N |P=0.214N P=0.544N P=0.290N P=0.301N |
|POLY 6 | P=0.052N P=1.000 P=0.533N P=0.229N |P=0.488N P=0.500N P=0.420N P=0.666N |
|LOGISTIC REGRESSION| P=0.109N (e) P=0.569 P=0.308N |P=0.228N P=0.641N P=0.528N P=0.357N |
|COCH-ARM / FISHERS | P=0.185N P=0.247 P=0.500 P=0.500N |P=0.231N P=0.500N P=0.309N P=0.309N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Heart: Atrium |
| Thrombosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 4.5% 0.0% 0.0% 0.0% |0.0% 0.0% 0.0% 2.3% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 0/34 (0%) 0/34 (0%) |0/36 (0%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | 561 --- --- --- |--- --- --- 497 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.166N P=0.229N P=0.251N P=0.237N |P=0.182 (e) (e) P=0.492 |
|POLY 3 | P=0.166N P=0.231N P=0.245N P=0.235N |P=0.180 (e) (e) P=0.491 |
|POLY 1.5 | P=0.164N P=0.232N P=0.241N P=0.234N |P=0.183 (e) (e) P=0.495 |
|POLY 6 | P=0.169N P=0.229N P=0.250N P=0.237N |P=0.176 (e) (e) P=0.486 |
|LOGISTIC REGRESSION| P=0.167N P=0.266N P=0.240N P=0.261N |P=0.163 (e) (e) P=0.488 |
|COCH-ARM / FISHERS | P=0.160N P=0.247N P=0.247N P=0.247N |P=0.186 (e) (e) P=0.500 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 7
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Intestine Small, Ileum: Peyer's Patch |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/44 (0%) 0/47 (0%) 1/45 (2%) 0/42 (0%) |1/48 (2%) 0/47 (0%) 2/49 (4%) 1/45 (2%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 2.5% 0.0% |2.3% 0.0% 5.0% 2.6% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 1/34 (3%) 0/34 (0%) |1/36 (3%) 0/34 (0%) 1/31 (3%) 1/29 (3%) |
|FIRST INCIDENCE | --- --- 733 (T) --- |735 (T) --- 645 735 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.638 (e) P=0.494 (e) |P=0.368 P=0.511N P=0.448 P=0.713 |
|POLY 3 | P=0.655 (e) P=0.501 (e) |P=0.368 P=0.499N P=0.468 P=0.729 |
|POLY 1.5 | P=0.651 (e) P=0.504 (e) |P=0.382 P=0.501N P=0.479 P=0.735 |
|POLY 6 | P=0.656 (e) P=0.498 (e) |P=0.357 P=0.498N P=0.460 P=0.723 |
|LOGISTIC REGRESSION| (e) (e) P=0.494 (e) |P=0.382 (e) P=0.482 P=0.713 |
|COCH-ARM / FISHERS | P=0.640 (e) P=0.506 (e) |P=0.408 P=0.505N P=0.508 P=0.736 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Intestine Small, Jejunum: Peyer's Patch |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/44 (2%) 0/48 (0%) 1/45 (2%) 1/43 (2%) |2/48 (4%) 1/47 (2%) 0/49 (0%) 0/43 (0%) |
|POLY-3 ADJUSTED (b)| 2.5% 0.0% 2.5% 2.5% |4.5% 2.3% 0.0% 0.0% |
|TERMINAL (d) | 1/35 (3%) 0/38 (0%) 1/34 (3%) 0/34 (0%) |2/36 (6%) 1/34 (3%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | 733 (T) --- 733 (T) 723 |735 (T) 735 (T) --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.457 P=0.484N P=0.755 P=0.757N |P=0.128N P=0.520N P=0.272N P=0.287N |
|POLY 3 | P=0.463 P=0.481N P=0.759N P=0.759N |P=0.123N P=0.498N P=0.260N P=0.274N |
|POLY 1.5 | P=0.461 P=0.480N P=0.756N P=0.759N |P=0.119N P=0.501N P=0.252N P=0.270N |
|POLY 6 | P=0.463 P=0.482N P=0.759 P=0.759N |P=0.126N P=0.496N P=0.267N P=0.277N |
|LOGISTIC REGRESSION| P=0.457 (e) P=0.755 P=0.762N |P=0.128N P=0.520N (e) (e) |
|COCH-ARM / FISHERS | P=0.453 P=0.478N P=0.747N P=0.747 |P=0.111N P=0.508N P=0.242N P=0.275N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 8
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 3/48 (6%) 2/49 (4%) 4/47 (9%) |1/50 (2%) 1/50 (2%) 1/50 (2%) 1/48 (2%) |
|POLY-3 ADJUSTED (b)| 4.6% 6.8% 4.7% 9.2% |2.2% 2.2% 2.5% 2.4% |
|TERMINAL (d) | 2/35 (6%) 3/36 (8%) 2/34 (6%) 2/34 (6%) |0/36 (0%) 0/34 (0%) 1/31 (3%) 1/29 (3%) |
|FIRST INCIDENCE | 733 (T) 733 (T) 733 (T) 665 |694 715 735 (T) 735 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.284 P=0.513 P=0.685 P=0.333 |P=0.569 P=0.755N P=0.725 P=0.724 |
|POLY 3 | P=0.299 P=0.500 P=0.683 P=0.334 |P=0.591 P=0.759N P=0.737 P=0.740 |
|POLY 1.5 | P=0.296 P=0.496 P=0.685 P=0.328 |P=0.601 P=0.760N P=0.745 P=0.745 |
|POLY 6 | P=0.302 P=0.506 P=0.680 P=0.340 |P=0.580 P=0.758N P=0.730 P=0.734 |
|LOGISTIC REGRESSION| P=0.295 P=0.513 P=0.685 P=0.332 |P=0.590 P=0.762N P=0.742 P=0.744 |
|COCH-ARM / FISHERS | P=0.283 P=0.480 P=0.684 P=0.310 |P=0.615 P=0.753N P=0.753N P=0.742 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Kidney |
| Glomerulosclerosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/49 (0%) 0/48 (0%) |2/50 (4%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |4.4% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 0/34 (0%) 0/34 (0%) |1/36 (3%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | --- --- --- --- |237 --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.173N P=0.248N P=0.256N P=0.263N |
|POLY 3 | (e) (e) (e) (e) |P=0.165N P=0.240N P=0.265N P=0.256N |
|POLY 1.5 | (e) (e) (e) (e) |P=0.162N P=0.241N P=0.256N P=0.249N |
|POLY 6 | (e) (e) (e) (e) |P=0.168N P=0.238N P=0.272N P=0.264N |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.145N P=0.171N P=0.132N P=0.221N |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.160N P=0.247N P=0.247N P=0.247N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 9
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Kidney |
| Hydronephrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 3/50 (6%) 2/49 (4%) 3/48 (6%) |1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 4.5% 6.5% 4.6% 6.7% |2.2% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/35 (0%) 2/38 (5%) 1/34 (3%) 2/34 (6%) |0/36 (0%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | 561 617 504 659 |729 --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.463 P=0.528 P=0.681 P=0.497 |P=0.381N P=0.516N P=0.534N P=0.547N |
|POLY 3 | P=0.474 P=0.518 P=0.684 P=0.501 |P=0.358N P=0.498N P=0.520N P=0.513N |
|POLY 1.5 | P=0.473 P=0.514 P=0.686 P=0.497 |P=0.356N P=0.500N P=0.513N P=0.507N |
|POLY 6 | P=0.474 P=0.524 P=0.681 P=0.503 |P=0.360N P=0.497N P=0.526N P=0.519N |
|LOGISTIC REGRESSION| P=0.438 P=0.475 P=0.680 P=0.460 |P=0.372N P=0.498N P=0.529N P=0.524N |
|COCH-ARM / FISHERS | P=0.462 P=0.500 P=0.684 P=0.480 |P=0.351N P=0.500N P=0.500N P=0.500N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Kidney |
| Metaplasia Osseous |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 4/49 (8%) 0/48 (0%) |2/50 (4%) 3/50 (6%) 1/50 (2%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 0.0% 2.2% 9.4% 0.0% |4.5% 6.6% 2.5% 2.4% |
|TERMINAL (d) | 0/35 (0%) 1/38 (3%) 3/34 (9%) 0/34 (0%) |2/36 (6%) 2/34 (6%) 1/31 (3%) 0/29 (0%) |
|FIRST INCIDENCE | --- 733 (T) 692 --- |735 (T) 715 735 (T) 646 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.544 P=0.516 P=0.060 (e) |P=0.295N P=0.482 P=0.552N P=0.553N |
|POLY 3 | P=0.584 P=0.509 P=0.056 (e) |P=0.256N P=0.505 P=0.535N P=0.519N |
|POLY 1.5 | P=0.578 P=0.507 P=0.057 (e) |P=0.246N P=0.501 P=0.523N P=0.511N |
|POLY 6 | P=0.587 P=0.512 P=0.056 (e) |P=0.266N P=0.509 P=0.545N P=0.528N |
|LOGISTIC REGRESSION| P=0.561 P=0.516 P=0.057 (e) |P=0.263N P=0.502 P=0.552N P=0.512N |
|COCH-ARM / FISHERS | P=0.554 P=0.500 P=0.056 (e) |P=0.232N P=0.500 P=0.500N P=0.500N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 10
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Kidney |
| Nephropathy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 48/50 (96%) 49/50 (98%) 45/49 (92%) 47/48 (98%) |43/50 (86%) 44/50 (88%) 40/50 (80%) 36/50 (72%) |
|POLY-3 ADJUSTED (b)| 99.5% 99.4% 97.0% 97.9% |88.7% 92.0% 84.8% 77.6% |
|TERMINAL (d) | 35/35 (100%) 38/38 (100%) 34/34 (100%) 33/34 (97%) |32/36 (89%) 31/34 (91%) 26/31 (84%) 24/29 (83%) |
|FIRST INCIDENCE | 457 473 393 501 |439 533 239 365 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.470 P=0.346N P=0.451N P=0.550N |P=0.496N P=0.393 P=0.384 P=0.559 |
|POLY 3 | P=0.282N P=0.994N P=0.413N P=0.595N |P=0.024N* P=0.419 P=0.391N P=0.106N |
|POLY 1.5 | P=0.379N P=0.912N P=0.289N P=0.676N |P=0.014N* P=0.418 P=0.337N P=0.078N |
|POLY 6 | P=0.197N P=1.000N P=0.820N P=0.525N |P=0.051N P=0.438 P=0.456N P=0.163N |
|LOGISTIC REGRESSION| P=0.357N P=0.804N P=0.305N P=0.674N |P=0.027N* P=0.488 P=0.389N P=0.093N |
|COCH-ARM / FISHERS | P=0.574 P=0.500 P=0.329N P=0.515 |P=0.018N* P=0.500 P=0.298N P=0.070N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Kidney: Capsule |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 2/49 (4%) 0/48 (0%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 0.0% 2.2% 4.7% 0.0% |0.0% 0.0% 0.0% 2.4% |
|TERMINAL (d) | 0/35 (0%) 1/38 (3%) 2/34 (6%) 0/34 (0%) |0/36 (0%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | --- 733 (T) 733 (T) --- |--- --- --- 710 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.608N P=0.516 P=0.232 (e) |P=0.171 (e) (e) P=0.478 |
|POLY 3 | P=0.584N P=0.509 P=0.230 (e) |P=0.178 (e) (e) P=0.488 |
|POLY 1.5 | P=0.587N P=0.507 P=0.232 (e) |P=0.182 (e) (e) P=0.493 |
|POLY 6 | P=0.582N P=0.512 P=0.228 (e) |P=0.174 (e) (e) P=0.482 |
|LOGISTIC REGRESSION| (e) P=0.516 P=0.232 (e) |P=0.179 (e) (e) P=0.491 |
|COCH-ARM / FISHERS | P=0.599N P=0.500 P=0.242 (e) |P=0.186 (e) (e) P=0.500 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 11
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Kidney: Cortex |
| Cyst |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 4/50 (8%) 0/49 (0%) 2/48 (4%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 4.6% 8.7% 0.0% 4.5% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 2/35 (6%) 4/38 (11%) 0/34 (0%) 2/34 (6%) |0/36 (0%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | 733 (T) 733 (T) --- 733 (T) |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.335N P=0.375 P=0.245N P=0.685 |(e) (e) (e) (e) |
|POLY 3 | P=0.316N P=0.358 P=0.244N P=0.691N |(e) (e) (e) (e) |
|POLY 1.5 | P=0.317N P=0.353 P=0.242N P=0.693 |(e) (e) (e) (e) |
|POLY 6 | P=0.316N P=0.365 P=0.246N P=0.688N |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.335N P=0.375 (e) P=0.685 |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.324N P=0.339 P=0.253N P=0.676 |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Kidney: Renal Tubule |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 3/49 (6%) 1/48 (2%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 4.6% 0.0% 7.1% 2.3% |0.0% 0.0% 0.0% 2.4% |
|TERMINAL (d) | 2/35 (6%) 0/38 (0%) 3/34 (9%) 1/34 (3%) |0/36 (0%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | 733 (T) --- 733 (T) 733 (T) |--- --- --- 717 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.535 P=0.220N P=0.487 P=0.510N |P=0.170 (e) (e) P=0.466 |
|POLY 3 | P=0.559 P=0.227N P=0.486 P=0.497N |P=0.178 (e) (e) P=0.488 |
|POLY 1.5 | P=0.556 P=0.230N P=0.489 P=0.501N |P=0.182 (e) (e) P=0.493 |
|POLY 6 | P=0.558 P=0.224N P=0.482 P=0.494N |P=0.173 (e) (e) P=0.482 |
|LOGISTIC REGRESSION| P=0.535 (e) P=0.487 P=0.510N |P=0.176 (e) (e) P=0.486 |
|COCH-ARM / FISHERS | P=0.546 P=0.247N P=0.490 P=0.515N |P=0.186 (e) (e) P=0.500 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 12
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Larynx |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 1/48 (2%) 0/48 (0%) |2/50 (4%) 2/50 (4%) 2/50 (4%) 1/50 (2%) |
|POLY-3 ADJUSTED (b)| 0.0% 2.2% 2.4% 0.0% |4.3% 4.3% 4.8% 2.3% |
|TERMINAL (d) | 0/35 (0%) 1/38 (3%) 0/34 (0%) 0/34 (0%) |0/36 (0%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | --- 733 (T) 504 --- |237 533 483 497 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.542N P=0.516 P=0.496 (e) |P=0.397N P=0.679N P=0.667 P=0.510N |
|POLY 3 | P=0.534N P=0.509 P=0.493 (e) |P=0.403N P=0.693N P=0.659 P=0.526N |
|POLY 1.5 | P=0.537N P=0.507 P=0.493 (e) |P=0.388N P=0.691 P=0.669 P=0.516N |
|POLY 6 | P=0.532N P=0.512 P=0.492 (e) |P=0.418N P=0.689N P=0.651 P=0.537N |
|LOGISTIC REGRESSION| P=0.590N P=0.516 P=0.453 (e) |P=0.331N P=0.652N P=0.511N P=0.470N |
|COCH-ARM / FISHERS | P=0.546N P=0.500 P=0.490 (e) |P=0.366N P=0.691N P=0.691N P=0.500N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Larynx: Squamous Epithelium |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 13/50 (26%) 11/48 (23%) 5/48 (10%) |11/50 (22%) 9/50 (18%) 7/50 (14%) 7/50 (14%) |
|POLY-3 ADJUSTED (b)| 23.8% 28.2% 26.2% 10.9% |23.2% 19.4% 16.2% 16.4% |
|TERMINAL (d) | 6/35 (17%) 10/38 (26%) 10/34 (29%) 1/34 (3%) |5/36 (14%) 6/34 (18%) 3/31 (10%) 5/29 (17%) |
|FIRST INCIDENCE | 54 710 609 501 |237 533 365 497 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.059N P=0.500 P=0.564 P=0.102N |P=0.307N P=0.426N P=0.322N P=0.354N |
|POLY 3 | P=0.039N* P=0.404 P=0.496 P=0.086N |P=0.243N P=0.423N P=0.286N P=0.292N |
|POLY 1.5 | P=0.042N* P=0.405 P=0.514 P=0.091N |P=0.214N P=0.422N P=0.264N P=0.262N |
|POLY 6 | P=0.037N* P=0.403 P=0.473 P=0.083N |P=0.278N P=0.427N P=0.307N P=0.330N |
|LOGISTIC REGRESSION| P=0.052N P=0.380 P=0.553 P=0.177N |P=0.150N P=0.394N P=0.124N P=0.188N |
|COCH-ARM / FISHERS | P=0.049N* P=0.408 P=0.553 P=0.100N |P=0.176N P=0.402N P=0.218N P=0.218N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 13
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Basophilic Focus |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 2/50 (4%) 2/50 (4%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 2.2% 4.7% 4.4% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/35 (0%) 1/38 (3%) 2/34 (6%) 2/34 (6%) |0/36 (0%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | --- 733 (T) 733 (T) 733 (T) |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.146 P=0.516 P=0.232 P=0.232 |(e) (e) (e) (e) |
|POLY 3 | P=0.168 P=0.509 P=0.232 P=0.243 |(e) (e) (e) (e) |
|POLY 1.5 | P=0.169 P=0.507 P=0.235 P=0.242 |(e) (e) (e) (e) |
|POLY 6 | P=0.166 P=0.512 P=0.229 P=0.242 |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| (e) P=0.516 P=0.232 P=0.232 |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.164 P=0.500 P=0.247 P=0.247 |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Clear Cell Focus |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 2/50 (4%) 1/50 (2%) |1/50 (2%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 4.4% 4.7% 2.2% |2.2% 0.0% 2.5% 0.0% |
|TERMINAL (d) | 0/35 (0%) 1/38 (3%) 2/34 (6%) 1/34 (3%) |1/36 (3%) 0/34 (0%) 1/31 (3%) 0/29 (0%) |
|FIRST INCIDENCE | --- 715 733 (T) 733 (T) |735 (T) --- 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.501 P=0.263 P=0.232 P=0.494 |P=0.510N P=0.511N P=0.728 P=0.543N |
|POLY 3 | P=0.533 P=0.248 P=0.232 P=0.505 |P=0.482N P=0.498N P=0.738 P=0.513N |
|POLY 1.5 | P=0.532 P=0.245 P=0.235 P=0.505 |P=0.474N P=0.500N P=0.746 P=0.507N |
|POLY 6 | P=0.531 P=0.251 P=0.229 P=0.505 |P=0.491N P=0.497N P=0.731 P=0.519N |
|LOGISTIC REGRESSION| P=0.513 P=0.250 P=0.232 P=0.494 |P=0.510N (e) P=0.728 (e) |
|COCH-ARM / FISHERS | P=0.523 P=0.247 P=0.247 P=0.500 |P=0.464N P=0.500N P=0.753N P=0.500N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 14
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Eosinophilic Focus |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 14/50 (28%) 14/50 (28%) 19/50 (38%) |5/50 (10%) 15/50 (30%) 11/50 (22%) 14/50 (28%) |
|POLY-3 ADJUSTED (b)| 25.0% 30.4% 32.2% 41.7% |11.1% 32.4% 26.9% 32.2% |
|TERMINAL (d) | 10/35 (29%) 11/38 (29%) 11/34 (32%) 15/34 (44%) |4/36 (11%) 11/34 (32%) 8/31 (26%) 10/29 (35%) |
|FIRST INCIDENCE | 699 710 586 591 |639 533 659 497 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.039 * P=0.419 P=0.295 P=0.056 |P=0.042 * P=0.012 * P=0.049 * P=0.008 ** |
|POLY 3 | P=0.058 P=0.369 P=0.306 P=0.071 |P=0.078 P=0.012 * P=0.052 P=0.013 * |
|POLY 1.5 | P=0.060 P=0.357 P=0.315 P=0.070 |P=0.092 P=0.011 * P=0.062 P=0.015 * |
|POLY 6 | P=0.055 P=0.388 P=0.296 P=0.071 |P=0.066 P=0.012 * P=0.045 * P=0.011 * |
|LOGISTIC REGRESSION| P=0.049 * P=0.397 P=0.276 P=0.067 |P=0.077 P=0.012 * P=0.048 * P=0.016 * |
|COCH-ARM / FISHERS | P=0.059 P=0.322 P=0.322 P=0.063 |P=0.118 P=0.011 * P=0.086 P=0.020 * |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Hematopoietic Cell Proliferation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 1/50 (2%) 2/50 (4%) 2/50 (4%) |3/50 (6%) 4/50 (8%) 5/50 (10%) 5/50 (10%) |
|POLY-3 ADJUSTED (b)| 6.7% 2.2% 4.5% 4.4% |6.6% 8.7% 11.7% 11.6% |
|TERMINAL (d) | 1/35 (3%) 1/38 (3%) 0/34 (0%) 0/34 (0%) |0/36 (0%) 1/34 (3%) 2/31 (7%) 1/29 (3%) |
|FIRST INCIDENCE | 561 733 (T) 232 555 |639 644 365 497 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.565N P=0.289N P=0.516N P=0.503N |P=0.228 P=0.512 P=0.297 P=0.298 |
|POLY 3 | P=0.557N P=0.295N P=0.504N P=0.491N |P=0.254 P=0.507 P=0.322 P=0.329 |
|POLY 1.5 | P=0.554N P=0.297N P=0.499N P=0.491N |P=0.271 P=0.502 P=0.334 P=0.341 |
|POLY 6 | P=0.561N P=0.293N P=0.511N P=0.492N |P=0.235 P=0.512 P=0.309 P=0.316 |
|LOGISTIC REGRESSION| P=0.578 P=0.318N P=0.524N P=0.539N |P=0.321 P=0.502 P=0.448 P=0.373 |
|COCH-ARM / FISHERS | P=0.555N P=0.309N P=0.500N P=0.500N |P=0.292 P=0.500 P=0.357 P=0.357 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 15
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Hyperplasia Lymphoid |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |1/50 (2%) 3/50 (6%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |2.2% 6.6% 2.5% 0.0% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 0/34 (0%) 0/34 (0%) |0/36 (0%) 2/34 (6%) 1/31 (3%) 0/29 (0%) |
|FIRST INCIDENCE | --- --- --- --- |694 729 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.177N P=0.293 P=0.725 P=0.521N |
|POLY 3 | (e) (e) (e) (e) |P=0.154N P=0.308 P=0.737 P=0.513N |
|POLY 1.5 | (e) (e) (e) (e) |P=0.147N P=0.306 P=0.745 P=0.508N |
|POLY 6 | (e) (e) (e) (e) |P=0.162N P=0.309 P=0.730 P=0.520N |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.162N P=0.309 P=0.742 P=0.501N |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.137N P=0.309 P=0.753N P=0.500N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 3/50 (6%) 1/50 (2%) 0/50 (0%) |3/50 (6%) 1/50 (2%) 1/50 (2%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 4.6% 6.5% 2.3% 0.0% |6.7% 2.2% 2.4% 0.0% |
|TERMINAL (d) | 2/35 (6%) 2/38 (5%) 0/34 (0%) 0/34 (0%) |2/36 (6%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | 733 (T) 715 502 --- |729 701 659 --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.085N P=0.542 P=0.504N P=0.245N |P=0.122N P=0.321N P=0.365N P=0.165N |
|POLY 3 | P=0.076N P=0.521 P=0.502N P=0.232N |P=0.105N P=0.301N P=0.339N P=0.130N |
|POLY 1.5 | P=0.076N P=0.516 P=0.500N P=0.232N |P=0.099N P=0.304N P=0.328N P=0.125N |
|POLY 6 | P=0.077N P=0.528 P=0.504N P=0.231N |P=0.110N P=0.297N P=0.348N P=0.136N |
|LOGISTIC REGRESSION| P=0.078N P=0.534 P=0.501N (e) |P=0.102N P=0.299N P=0.339N P=0.148N |
|COCH-ARM / FISHERS | P=0.078N P=0.500 P=0.500N P=0.247N |P=0.093N P=0.309N P=0.309N P=0.121N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 16
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Necrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 10/50 (20%) 6/50 (12%) 5/50 (10%) 4/50 (8%) |3/50 (6%) 4/50 (8%) 7/50 (14%) 5/50 (10%) |
|POLY-3 ADJUSTED (b)| 22.1% 12.8% 11.4% 8.7% |6.6% 8.8% 16.4% 11.6% |
|TERMINAL (d) | 4/35 (11%) 4/38 (11%) 3/34 (9%) 1/34 (3%) |2/36 (6%) 1/34 (3%) 2/31 (7%) 2/29 (7%) |
|FIRST INCIDENCE | 457 473 502 561 |533 688 483 464 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.100N P=0.177N P=0.164N P=0.089N |P=0.186 P=0.496 P=0.127 P=0.274 |
|POLY 3 | P=0.076N P=0.182N P=0.142N P=0.066N |P=0.216 P=0.503 P=0.133 P=0.325 |
|POLY 1.5 | P=0.075N P=0.187N P=0.136N P=0.067N |P=0.236 P=0.499 P=0.140 P=0.339 |
|POLY 6 | P=0.079N P=0.177N P=0.151N P=0.065N |P=0.196 P=0.507 P=0.130 P=0.310 |
|LOGISTIC REGRESSION| P=0.077N P=0.220N P=0.131N P=0.081N |P=0.278 P=0.501 P=0.197 P=0.373 |
|COCH-ARM / FISHERS | P=0.075N P=0.207N P=0.131N P=0.074N |P=0.260 P=0.500 P=0.159 P=0.357 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lung |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 6/50 (12%) 6/50 (12%) 3/50 (6%) |9/50 (18%) 6/50 (12%) 5/50 (10%) 5/50 (10%) |
|POLY-3 ADJUSTED (b)| 11.4% 13.1% 13.7% 6.7% |19.5% 13.2% 12.2% 11.4% |
|TERMINAL (d) | 5/35 (14%) 6/38 (16%) 4/34 (12%) 3/34 (9%) |6/36 (17%) 5/34 (15%) 4/31 (13%) 1/29 (3%) |
|FIRST INCIDENCE | 733 (T) 733 (T) 609 733 (T) |533 688 645 497 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.283N P=0.558 P=0.480 P=0.371N |P=0.298N P=0.319N P=0.283N P=0.297N |
|POLY 3 | P=0.242N P=0.531 P=0.497 P=0.343N |P=0.221N P=0.297N P=0.265N P=0.223N |
|POLY 1.5 | P=0.241N P=0.523 P=0.500 P=0.344N |P=0.205N P=0.297N P=0.239N P=0.210N |
|POLY 6 | P=0.246N P=0.542 P=0.497 P=0.342N |P=0.238N P=0.300N P=0.289N P=0.239N |
|LOGISTIC REGRESSION| P=0.251N P=0.558 P=0.485 P=0.371N |P=0.191N P=0.288N P=0.219N P=0.171N |
|COCH-ARM / FISHERS | P=0.246N P=0.500 P=0.500 P=0.357N |P=0.185N P=0.288N P=0.194N P=0.194N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 17
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lung |
| Infiltration Cellular Histiocyte |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 10/50 (20%) 45/50 (90%) 48/50 (96%) |2/50 (4%) 13/50 (26%) 48/50 (96%) 49/50 (98%) |
|POLY-3 ADJUSTED (b)| 6.7% 21.6% 94.5% 98.5% |4.5% 28.3% 99.5% 98.4% |
|TERMINAL (d) | 1/35 (3%) 8/38 (21%) 33/34 (97%) 34/34 (100%)|2/36 (6%) 10/34 (29%) 31/31 (100%) 29/29 (100%) |
|FIRST INCIDENCE | 561 617 393 501 |735 (T) 644 239 365 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P<0.001 ** P=0.057 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.002 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.041 * P<0.001 ** P<0.001 ** |P<0.001 ** P=0.002 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.039 * P<0.001 ** P<0.001 ** |P<0.001 ** P=0.002 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.043 * P<0.001 ** P<0.001 ** |P<0.001 ** P=0.002 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.040 * P<0.001 ** P<0.001 ** |P<0.001 ** P=0.003 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.036 * P<0.001 ** P<0.001 ** |P<0.001 ** P=0.002 ** P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lung |
| Inflammation Chronic Focal |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 3/50 (6%) 3/50 (6%) 12/50 (24%) |1/50 (2%) 2/50 (4%) 11/50 (22%) 18/50 (36%) |
|POLY-3 ADJUSTED (b)| 2.3% 6.5% 6.7% 26.6% |2.2% 4.4% 26.2% 42.1% |
|TERMINAL (d) | 0/35 (0%) 1/38 (3%) 1/34 (3%) 10/34 (29%) |1/36 (3%) 1/34 (3%) 6/31 (19%) 15/29 (52%) |
|FIRST INCIDENCE | 561 617 393 699 |735 (T) 644 609 646 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P<0.001 ** P=0.336 P=0.304 P=0.002 ** |P<0.001 ** P=0.497 P=0.002 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.321 P=0.305 P<0.001 ** |P<0.001 ** P=0.506 P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.317 P=0.307 P<0.001 ** |P<0.001 ** P=0.502 P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.327 P=0.302 P<0.001 ** |P<0.001 ** P=0.510 P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.265 P=0.269 P=0.002 ** |P<0.001 ** P=0.500 P=0.002 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.309 P=0.309 P<0.001 ** |P<0.001 ** P=0.500 P=0.002 ** P<0.001 ** |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 18
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lung |
| Inflammation Focal |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 8/50 (16%) 23/50 (46%) |0/50 (0%) 0/50 (0%) 2/50 (4%) 14/50 (28%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 18.6% 48.9% |0.0% 0.0% 4.9% 32.9% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 8/34 (24%) 19/34 (56%) |0/36 (0%) 0/34 (0%) 2/31 (7%) 12/29 (41%) |
|FIRST INCIDENCE | --- --- 733 (T) 406 |--- --- 735 (T) 646 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P<0.001 ** (e) P=0.004 ** P<0.001 ** |P<0.001 ** (e) P=0.206 P<0.001 ** |
|POLY 3 | P<0.001 ** (e) P=0.003 ** P<0.001 ** |P<0.001 ** (e) P=0.216 P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.003 ** P<0.001 ** |P<0.001 ** (e) P=0.223 P<0.001 ** |
|POLY 6 | P<0.001 ** (e) P=0.003 ** P<0.001 ** |P<0.001 ** (e) P=0.209 P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.004 ** P<0.001 ** |P<0.001 ** (e) P=0.206 P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.003 ** P<0.001 ** |P<0.001 ** (e) P=0.247 P<0.001 ** |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lung: Alveolar Epithelium |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 9/50 (18%) 39/50 (78%) 45/50 (90%) |2/50 (4%) 5/50 (10%) 27/50 (54%) 43/50 (86%) |
|POLY-3 ADJUSTED (b)| 9.1% 19.6% 86.3% 92.5% |4.5% 11.0% 62.5% 92.2% |
|TERMINAL (d) | 3/35 (9%) 9/38 (24%) 33/34 (97%) 33/34 (97%) |2/36 (6%) 5/34 (15%) 20/31 (65%) 27/29 (93%) |
|FIRST INCIDENCE | 686 733 (T) 393 501 |735 (T) 735 (T) 365 497 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P<0.001 ** P=0.148 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.192 P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.130 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.220 P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.127 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.217 P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.134 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.222 P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.144 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.192 P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.117 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.218 P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 19
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lung: Alveolus |
| Foreign Body |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 4/50 (8%) 46/50 (92%) 50/50 (100%)|0/50 (0%) 8/50 (16%) 48/50 (96%) 49/50 (98%) |
|POLY-3 ADJUSTED (b)| 0.0% 8.7% 95.6% 100.0% |0.0% 17.7% 99.5% 98.4% |
|TERMINAL (d) | 0/35 (0%) 4/38 (11%) 33/34 (97%) 34/34 (100%)|0/36 (0%) 8/34 (24%) 31/31 (100%) 29/29 (100%) |
|FIRST INCIDENCE | --- 733 (T) 393 406 |--- 735 (T) 239 365 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P<0.001 ** P=0.074 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.003 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.066 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.004 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.065 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.004 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.068 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.004 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.074 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.003 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.059 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.003 ** P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lung: Alveolus |
| Proteinosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 4/50 (8%) 49/50 (98%) 50/50 (100%)|0/50 (0%) 4/50 (8%) 49/50 (98%) 50/50 (100%) |
|POLY-3 ADJUSTED (b)| 2.3% 8.7% 99.9% 100.0% |0.0% 8.8% 99.9% 100.0% |
|TERMINAL (d) | 0/35 (0%) 3/38 (8%) 34/34 (100%) 34/34 (100%)|0/36 (0%) 4/34 (12%) 31/31 (100%) 29/29 (100%) |
|FIRST INCIDENCE | 561 710 393 406 |--- 735 (T) 281 365 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P<0.001 ** P=0.208 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.056 P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.189 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.061 P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.187 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.061 P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.192 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.062 P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.176 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.056 P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.181 P<0.001 ** P<0.001 ** |P<0.001 ** P=0.059 P<0.001 ** P<0.001 ** |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 20
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lung: Perivascular |
| Infiltration Cellular Mononuclear Cell |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |2/50 (4%) 0/50 (0%) 2/50 (4%) 2/50 (4%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |4.5% 0.0% 4.9% 4.8% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 0/34 (0%) 0/34 (0%) |2/36 (6%) 0/34 (0%) 2/31 (7%) 2/29 (7%) |
|FIRST INCIDENCE | --- --- --- --- |735 (T) --- 735 (T) 735 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.281 P=0.251N P=0.641 P=0.615 |
|POLY 3 | (e) (e) (e) (e) |P=0.324 P=0.235N P=0.658 P=0.671 |
|POLY 1.5 | (e) (e) (e) (e) |P=0.339 P=0.237N P=0.670 P=0.681 |
|POLY 6 | (e) (e) (e) (e) |P=0.310 P=0.233N P=0.647 P=0.660 |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.281 (e) P=0.641 P=0.615 |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.356 P=0.247N P=0.691N P=0.691N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lymph Node |
| Angiectasis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/2 (0%) 0/0 (0%) 0/2 (0%) 0/1 (0%) |2/4 (50%) 1/8 (13%) 2/5 (40%) 0/6 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |65.8% 14.4% 56.3% 0.0% |
|TERMINAL (d) | 0/1 (0%) 0/0 (0%) 0/2 (0%) 0/0 (0%) |2/2 (100%) 1/5 (20%) 2/3 (67%) 0/3 (0%) |
|FIRST INCIDENCE | --- --- --- --- |735 (T) 735 (T) 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.204N P=0.157N P=0.581N P=0.122N |
|POLY 3 | (e) (e) (e) (e) |P=0.160N P=0.183N P=0.706N P=0.057N |
|POLY 1.5 | (e) (e) (e) (e) |P=0.170N P=0.208N P=0.694N P=0.074N |
|POLY 6 | (e) (e) (e) (e) |P=0.151N P=0.151N P=0.687N P=0.038N* |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.204N P=0.157N P=0.581N (e) |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.194N P=0.236N P=0.643N P=0.133N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 21
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lymph Node, Bronchial |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 5/38 (13%) 7/37 (19%) 17/40 (43%) 24/41 (59%) |10/39 (26%) 12/43 (28%) 13/42 (31%) 23/42 (55%) |
|POLY-3 ADJUSTED (b)| 14.5% 20.3% 46.7% 60.9% |27.2% 29.9% 36.1% 61.9% |
|TERMINAL (d) | 4/28 (14%) 6/28 (21%) 15/31 (48%) 22/32 (69%) |8/29 (28%) 10/31 (32%) 12/28 (43%) 19/26 (73%) |
|FIRST INCIDENCE | 702 617 672 591 |533 659 711 628 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P<0.001 ** P=0.388 P=0.006 ** P<0.001 ** |P<0.001 ** P=0.472 P=0.265 P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.374 P=0.002 ** P<0.001 ** |P<0.001 ** P=0.499 P=0.288 P=0.002 ** |
|POLY 1.5 | P<0.001 ** P=0.367 P=0.002 ** P<0.001 ** |P<0.001 ** P=0.500 P=0.327 P=0.003 ** |
|POLY 6 | P<0.001 ** P=0.385 P=0.002 ** P<0.001 ** |P<0.001 ** P=0.500 P=0.245 P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.370 P=0.004 ** P<0.001 ** |P<0.001 ** P=0.508 P=0.290 P=0.003 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.358 P=0.004 ** P<0.001 ** |P=0.002 ** P=0.508 P=0.389 P=0.007 ** |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lymph Node, Mandibular |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/37 (5%) 3/40 (8%) 0/28 (0%) 0/32 (0%) |1/35 (3%) 0/37 (0%) 1/43 (2%) 2/43 (5%) |
|POLY-3 ADJUSTED (b)| 6.3% 8.2% 0.0% 0.0% |3.3% 0.0% 2.9% 5.5% |
|TERMINAL (d) | 1/26 (4%) 3/30 (10%) 0/18 (0%) 0/23 (0%) |1/25 (4%) 0/25 (0%) 1/27 (4%) 2/25 (8%) |
|FIRST INCIDENCE | 686 733 (T) --- --- |735 (T) --- 735 (T) 735 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.071N P=0.556 P=0.292N P=0.256N |P=0.202 P=0.500N P=0.745N P=0.500 |
|POLY 3 | P=0.067N P=0.563 P=0.307N P=0.251N |P=0.235 P=0.484N P=0.732N P=0.559 |
|POLY 1.5 | P=0.067N P=0.556 P=0.304N P=0.255N |P=0.244 P=0.487N P=0.726N P=0.565 |
|POLY 6 | P=0.067N P=0.571 P=0.309N P=0.248N |P=0.226 P=0.481N P=0.737N P=0.552 |
|LOGISTIC REGRESSION| P=0.067N P=0.575 P=0.304N P=0.255N |P=0.202 (e) P=0.745N P=0.500 |
|COCH-ARM / FISHERS | P=0.070N P=0.537 P=0.320N P=0.284N |P=0.251 P=0.486N P=0.699N P=0.578 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 22
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lymph Node, Mediastinal |
| Hematopoietic Cell Proliferation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/38 (0%) 1/36 (3%) 0/38 (0%) 0/33 (0%) |0/40 (0%) 0/43 (0%) 2/49 (4%) 0/45 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 2.9% 0.0% 0.0% |0.0% 0.0% 5.0% 0.0% |
|TERMINAL (d) | 0/29 (0%) 1/31 (3%) 0/28 (0%) 0/25 (0%) |0/29 (0%) 0/31 (0%) 1/30 (3%) 0/27 (0%) |
|FIRST INCIDENCE | --- 733 (T) --- --- |--- --- 421 --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.477N P=0.513 (e) (e) |P=0.525 (e) P=0.239 (e) |
|POLY 3 | P=0.462N P=0.498 (e) (e) |P=0.516 (e) P=0.258 (e) |
|POLY 1.5 | P=0.464N P=0.495 (e) (e) |P=0.532 (e) P=0.265 (e) |
|POLY 6 | P=0.460N P=0.502 (e) (e) |P=0.503 (e) P=0.253 (e) |
|LOGISTIC REGRESSION| (e) P=0.513 (e) (e) |P=0.676 (e) P=0.395 (e) |
|COCH-ARM / FISHERS | P=0.465N P=0.486 (e) (e) |P=0.561 (e) P=0.300 (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lymph Node, Mediastinal |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/38 (3%) 1/36 (3%) 4/38 (11%) 3/33 (9%) |5/40 (13%) 3/43 (7%) 6/49 (12%) 8/45 (18%) |
|POLY-3 ADJUSTED (b)| 2.9% 2.9% 11.5% 9.4% |13.3% 7.4% 15.1% 20.9% |
|TERMINAL (d) | 1/29 (3%) 1/31 (3%) 2/28 (7%) 0/25 (0%) |2/29 (7%) 2/31 (7%) 5/30 (17%) 7/27 (26%) |
|FIRST INCIDENCE | 733 (T) 733 (T) 645 501 |533 715 659 646 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.119 P=0.747N P=0.168 P=0.301 |P=0.065 P=0.344N P=0.480 P=0.228 |
|POLY 3 | P=0.117 P=0.758 P=0.176 P=0.274 |P=0.089 P=0.316N P=0.541 P=0.283 |
|POLY 1.5 | P=0.113 P=0.754 P=0.175 P=0.267 |P=0.104 P=0.316N P=0.572 P=0.308 |
|POLY 6 | P=0.121 P=0.758N P=0.179 P=0.281 |P=0.078 P=0.317N P=0.516 P=0.261 |
|LOGISTIC REGRESSION| P=0.101 P=0.747N P=0.176 P=0.197 |P=0.096 P=0.350N P=0.591 P=0.320 |
|COCH-ARM / FISHERS | P=0.106 P=0.740 P=0.179 P=0.255 |P=0.136 P=0.316N P=0.609N P=0.357 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 23
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Lymph Node, Mesenteric |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 3/48 (6%) 5/49 (10%) 4/50 (8%) 4/46 (9%) |3/49 (6%) 3/49 (6%) 5/50 (10%) 6/47 (13%) |
|POLY-3 ADJUSTED (b)| 6.9% 10.9% 9.3% 9.4% |6.7% 6.7% 12.1% 14.5% |
|TERMINAL (d) | 2/35 (6%) 2/38 (5%) 3/34 (9%) 3/33 (9%) |3/36 (8%) 2/34 (6%) 3/31 (10%) 2/28 (7%) |
|FIRST INCIDENCE | 686 609 729 723 |735 (T) 659 645 365 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.494 P=0.406 P=0.481 P=0.478 |P=0.080 P=0.647 P=0.280 P=0.180 |
|POLY 3 | P=0.509 P=0.381 P=0.489 P=0.485 |P=0.098 P=0.661 P=0.311 P=0.205 |
|POLY 1.5 | P=0.510 P=0.375 P=0.500 P=0.482 |P=0.106 P=0.657 P=0.326 P=0.211 |
|POLY 6 | P=0.504 P=0.392 P=0.478 P=0.487 |P=0.092 P=0.659N P=0.301 P=0.199 |
|LOGISTIC REGRESSION| P=0.512 P=0.367 P=0.478 P=0.490 |P=0.126 P=0.660 P=0.306 P=0.328 |
|COCH-ARM / FISHERS | P=0.511 P=0.369 P=0.523 P=0.476 |P=0.115 P=0.661N P=0.369 P=0.223 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) |4/50 (8%) 4/50 (8%) 2/50 (4%) 3/49 (6%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |8.9% 8.8% 4.9% 7.3% |
|TERMINAL (d) | 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) |4/36 (11%) 3/34 (9%) 2/31 (7%) 2/29 (7%) |
|FIRST INCIDENCE | --- --- --- --- |735 (T) 701 735 (T) 717 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.453N P=0.619 P=0.407N P=0.613N |
|POLY 3 | (e) (e) (e) (e) |P=0.399N P=0.636N P=0.384N P=0.546N |
|POLY 1.5 | (e) (e) (e) (e) |P=0.380N P=0.641N P=0.368N P=0.531N |
|POLY 6 | (e) (e) (e) (e) |P=0.418N P=0.631N P=0.398N P=0.563N |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.443N P=0.641N P=0.407N P=0.595N |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.354N P=0.643N P=0.339N P=0.511N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 24
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Mesentery |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/4 (0%) 0/5 (0%) 0/4 (0%) 0/6 (0%) |0/8 (0%) 0/9 (0%) 2/16 (13%) 0/13 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |0.0% 0.0% 15.6% 0.0% |
|TERMINAL (d) | 0/3 (0%) 0/4 (0%) 0/3 (0%) 0/5 (0%) |0/4 (0%) 0/4 (0%) 0/6 (0%) 0/7 (0%) |
|FIRST INCIDENCE | --- --- --- --- |--- --- 421 --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.511 (e) P=0.221 (e) |
|POLY 3 | (e) (e) (e) (e) |P=0.584 (e) P=0.376 (e) |
|POLY 1.5 | (e) (e) (e) (e) |P=0.610 (e) P=0.383 (e) |
|POLY 6 | (e) (e) (e) (e) |P=0.559 (e) P=0.367 (e) |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.665N (e) P=0.498 (e) |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.650 (e) P=0.435 (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Mesentery: Fat |
| Necrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/4 (25%) 5/5 (100%) 3/4 (75%) 6/6 (100%) |4/8 (50%) 9/9 (100%) 13/16 (81%) 11/13 (85%) |
|POLY-3 ADJUSTED (b)| 28.8% 100.0% 75.3% 100.0% |55.2% 100.0% 92.1% 94.8% |
|TERMINAL (d) | 1/3 (33%) 4/4 (100%) 3/3 (100%) 5/5 (100%) |3/4 (75%) 4/4 (100%) 6/6 (100%) 7/7 (100%) |
|FIRST INCIDENCE | 733 (T) 715 733 (T) 665 |645 533 421 505 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.111 P=0.086 P=0.215 P=0.064 |P=0.134 P=0.067 P=0.013 * P=0.077 |
|POLY 3 | P=0.084 P=0.019 * P=0.299 P=0.009 ** |P=0.086 P=0.027 * P=0.045 * P=0.038 * |
|POLY 1.5 | P=0.057 P=0.012 * P=0.272 P=0.005 ** |P=0.155 P=0.020 * P=0.064 P=0.057 |
|POLY 6 | P=0.131 P=0.037 * P=0.335 P=0.021 * |P=0.046 * P=0.041 * P=0.033 * P=0.030 * |
|LOGISTIC REGRESSION| P=0.103 P=0.088 P=0.215 P=0.048 * |P=0.115 P=0.033 * P=0.051 P=0.038 * |
|COCH-ARM / FISHERS | P=0.079 P=0.048 * P=0.243 P=0.033 * |P=0.301 P=0.029 * P=0.134 P=0.115 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 25
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Nose |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 3/49 (6%) 2/49 (4%) 1/48 (2%) |2/50 (4%) 0/49 (0%) 4/50 (8%) 4/50 (8%) |
|POLY-3 ADJUSTED (b)| 0.0% 6.6% 4.7% 2.3% |4.4% 0.0% 9.3% 9.3% |
|TERMINAL (d) | 0/34 (0%) 3/38 (8%) 1/34 (3%) 0/34 (0%) |0/36 (0%) 0/34 (0%) 1/31 (3%) 3/29 (10%) |
|FIRST INCIDENCE | --- 733 (T) 608 699 |694 --- 239 490 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.580N P=0.141 P=0.242 P=0.500 |P=0.057 P=0.234N P=0.300 P=0.276 |
|POLY 3 | P=0.548N P=0.128 P=0.235 P=0.507 |P=0.061 P=0.237N P=0.313 P=0.313 |
|POLY 1.5 | P=0.553N P=0.126 P=0.237 P=0.504 |P=0.067 P=0.239N P=0.322 P=0.324 |
|POLY 6 | P=0.543N P=0.132 P=0.234 P=0.509 |P=0.055 P=0.236N P=0.305 P=0.300 |
|LOGISTIC REGRESSION| P=0.565N P=0.141 P=0.237 P=0.497 |P=0.091 P=0.242N P=0.473 P=0.343 |
|COCH-ARM / FISHERS | P=0.571N P=0.121 P=0.247 P=0.495 |P=0.077 P=0.253N P=0.339 P=0.339 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Nose: Olfactory Epithelium |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 7/49 (14%) 2/49 (4%) 5/49 (10%) 8/48 (17%) |3/50 (6%) 1/49 (2%) 7/50 (14%) 4/50 (8%) |
|POLY-3 ADJUSTED (b)| 16.3% 4.4% 11.9% 18.0% |6.7% 2.2% 16.9% 9.2% |
|TERMINAL (d) | 7/34 (21%) 2/38 (5%) 5/34 (15%) 6/34 (18%) |3/36 (8%) 1/34 (3%) 5/31 (16%) 2/29 (7%) |
|FIRST INCIDENCE | 733 (T) 733 (T) 733 (T) 699 |735 (T) 735 (T) 553 497 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.143 P=0.055N P=0.376N P=0.502 |P=0.115 P=0.325N P=0.110 P=0.409 |
|POLY 3 | P=0.162 P=0.066N P=0.391N P=0.530 |P=0.151 P=0.302N P=0.127 P=0.480 |
|POLY 1.5 | P=0.163 P=0.070N P=0.384N P=0.518 |P=0.164 P=0.307N P=0.136 P=0.489 |
|POLY 6 | P=0.159 P=0.062N P=0.398N P=0.540 |P=0.140 P=0.299N P=0.121 P=0.471 |
|LOGISTIC REGRESSION| P=0.161 P=0.055N P=0.376N P=0.536 |P=0.179 P=0.325N P=0.130 P=0.510 |
|COCH-ARM / FISHERS | P=0.161 P=0.080N P=0.380N P=0.482 |P=0.183 P=0.316N P=0.159 P=0.500 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 26
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Nose: Olfactory Epithelium |
| Degeneration Hyaline |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/49 (2%) 4/49 (8%) 6/49 (12%) 1/48 (2%) |3/50 (6%) 1/49 (2%) 10/50 (20%) 5/50 (10%) |
|POLY-3 ADJUSTED (b)| 2.3% 8.9% 14.2% 2.3% |6.7% 2.2% 23.6% 11.9% |
|TERMINAL (d) | 1/34 (3%) 4/38 (11%) 5/34 (15%) 1/34 (3%) |3/36 (8%) 1/34 (3%) 6/31 (19%) 4/29 (14%) |
|FIRST INCIDENCE | 733 (T) 733 (T) 715 733 (T) |735 (T) 735 (T) 239 714 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.484N P=0.214 P=0.059 P=0.762 |P=0.044 * P=0.325N P=0.023 * P=0.249 |
|POLY 3 | P=0.434N P=0.195 P=0.052 P=0.754N |P=0.054 P=0.302N P=0.025 * P=0.323 |
|POLY 1.5 | P=0.441N P=0.190 P=0.054 P=0.756N |P=0.065 P=0.307N P=0.028 * P=0.337 |
|POLY 6 | P=0.431N P=0.201 P=0.051 P=0.752N |P=0.045 * P=0.299N P=0.023 * P=0.307 |
|LOGISTIC REGRESSION| P=0.464N P=0.214 P=0.051 P=0.762 |P=0.080 P=0.325N P=0.036 * P=0.275 |
|COCH-ARM / FISHERS | P=0.466N P=0.181 P=0.056 P=0.747 |P=0.087 P=0.316N P=0.036 * P=0.357 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Nose: Respiratory Epithelium |
| Degeneration Hyaline |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/49 (2%) 2/49 (4%) 2/49 (4%) 1/48 (2%) |15/50 (30%) 17/49 (35%) 21/50 (42%) 17/50 (34%) |
|POLY-3 ADJUSTED (b)| 2.3% 4.4% 4.8% 2.3% |32.9% 37.0% 48.6% 38.4% |
|TERMINAL (d) | 1/34 (3%) 2/38 (5%) 2/34 (6%) 1/34 (3%) |14/36 (39%) 14/34 (41%) 15/31 (48%) 13/29 (45%) |
|FIRST INCIDENCE | 733 (T) 733 (T) 733 (T) 733 (T) |439 533 239 490 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.543N P=0.539 P=0.500 P=0.762 |P=0.132 P=0.349 P=0.061 P=0.187 |
|POLY 3 | P=0.516N P=0.518 P=0.494 P=0.754N |P=0.287 P=0.425 P=0.094 P=0.371 |
|POLY 1.5 | P=0.518N P=0.513 P=0.497 P=0.756N |P=0.324 P=0.407 P=0.109 P=0.390 |
|POLY 6 | P=0.516N P=0.525 P=0.490 P=0.752N |P=0.253 P=0.441 P=0.087 P=0.350 |
|LOGISTIC REGRESSION| P=0.543N P=0.539 P=0.500 P=0.762 |P=0.314 P=0.416 P=0.107 P=0.379 |
|COCH-ARM / FISHERS | P=0.529N P=0.500 P=0.500 P=0.747 |P=0.375 P=0.388 P=0.149 P=0.415 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 27
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Nose: Respiratory Epithelium |
| Metaplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 0/49 (0%) 0/49 (0%) 0/48 (0%) |0/50 (0%) 0/49 (0%) 2/50 (4%) 2/50 (4%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |0.0% 0.0% 4.8% 4.7% |
|TERMINAL (d) | 0/34 (0%) 0/38 (0%) 0/34 (0%) 0/34 (0%) |0/36 (0%) 0/34 (0%) 1/31 (3%) 1/29 (3%) |
|FIRST INCIDENCE | --- --- --- --- |--- --- 239 682 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.057 (e) P=0.225 P=0.205 |
|POLY 3 | (e) (e) (e) (e) |P=0.060 (e) P=0.220 P=0.224 |
|POLY 1.5 | (e) (e) (e) (e) |P=0.065 (e) P=0.227 P=0.230 |
|POLY 6 | (e) (e) (e) (e) |P=0.056 (e) P=0.215 P=0.219 |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.077 (e) P=0.332 P=0.227 |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.071 (e) P=0.247 P=0.247 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Ovary |
| Angiectasis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | |2/49 (4%) 0/50 (0%) 2/50 (4%) 0/46 (0%) |
|POLY-3 ADJUSTED (b)| |4.5% 0.0% 4.9% 0.0% |
|TERMINAL (d) | |2/36 (6%) 0/34 (0%) 2/31 (7%) 0/28 (0%) |
|FIRST INCIDENCE | |735 (T) --- 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | |P=0.394N P=0.251N P=0.641 P=0.295N |
|POLY 3 | |P=0.373N P=0.235N P=0.658 P=0.272N |
|POLY 1.5 | |P=0.360N P=0.236N P=0.671 P=0.265N |
|POLY 6 | |P=0.385N P=0.233N P=0.647 P=0.280N |
|LOGISTIC REGRESSION| |P=0.394N (e) P=0.641 (e) |
|COCH-ARM / FISHERS | |P=0.344N P=0.242N P=0.684N P=0.263N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 28
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Ovary |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | |3/49 (6%) 2/50 (4%) 2/50 (4%) 0/46 (0%) |
|POLY-3 ADJUSTED (b)| |6.7% 4.4% 4.9% 0.0% |
|TERMINAL (d) | |2/36 (6%) 0/34 (0%) 2/31 (7%) 0/28 (0%) |
|FIRST INCIDENCE | |729 715 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | |P=0.137N P=0.523N P=0.570N P=0.170N |
|POLY 3 | |P=0.123N P=0.494N P=0.545N P=0.148N |
|POLY 1.5 | |P=0.115N P=0.497N P=0.529N P=0.141N |
|POLY 6 | |P=0.132N P=0.491N P=0.559N P=0.155N |
|LOGISTIC REGRESSION| |P=0.134N P=0.494N P=0.570N P=0.162N |
|COCH-ARM / FISHERS | |P=0.102N P=0.490N P=0.490N P=0.133N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Ovary |
| Cyst |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | |18/49 (37%) 17/50 (34%) 23/50 (46%) 15/46 (33%) |
|POLY-3 ADJUSTED (b)| |38.9% 36.2% 51.2% 36.3% |
|TERMINAL (d) | |15/36 (42%) 11/34 (32%) 13/31 (42%) 7/28 (25%) |
|FIRST INCIDENCE | |439 302 239 464 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | |P=0.379 P=0.546N P=0.107 P=0.561 |
|POLY 3 | |P=0.480 P=0.477N P=0.164 P=0.486N |
|POLY 1.5 | |P=0.514 P=0.484N P=0.178 P=0.466N |
|POLY 6 | |P=0.460 P=0.466N P=0.164 P=0.497N |
|LOGISTIC REGRESSION| |P=0.487N P=0.469N P=0.233 P=0.397N |
|COCH-ARM / FISHERS | |P=0.500N P=0.470N P=0.232 P=0.419N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 29
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Pancreas |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 13/50 (26%) 7/50 (14%) 9/49 (18%) 6/47 (13%) |5/50 (10%) 10/50 (20%) 11/50 (22%) 2/49 (4%) |
|POLY-3 ADJUSTED (b)| 28.2% 15.0% 20.6% 13.8% |11.1% 21.9% 26.4% 4.8% |
|TERMINAL (d) | 8/35 (23%) 4/38 (11%) 6/34 (18%) 5/34 (15%) |4/36 (11%) 9/34 (27%) 8/31 (26%) 1/29 (3%) |
|FIRST INCIDENCE | 457 473 608 645 |707 659 365 497 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.150N P=0.087N P=0.270N P=0.075N |P=0.194N P=0.113 P=0.051 P=0.295N |
|POLY 3 | P=0.147N P=0.096N P=0.277N P=0.076N |P=0.135N P=0.134 P=0.058 P=0.244N |
|POLY 1.5 | P=0.144N P=0.096N P=0.265N P=0.075N |P=0.121N P=0.131 P=0.067 P=0.236N |
|POLY 6 | P=0.153N P=0.095N P=0.288N P=0.079N |P=0.152N P=0.137 P=0.052 P=0.254N |
|LOGISTIC REGRESSION| P=0.150N P=0.119N P=0.251N P=0.088N |P=0.130N P=0.136 P=0.063 P=0.229N |
|COCH-ARM / FISHERS | P=0.146N P=0.105N P=0.251N P=0.082N |P=0.110N P=0.131 P=0.086 P=0.226N |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Pancreas |
| Cytoplasmic Alteration |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/49 (0%) 0/47 (0%) |1/50 (2%) 1/50 (2%) 2/50 (4%) 1/49 (2%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |2.2% 2.2% 4.9% 2.4% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 0/34 (0%) 0/34 (0%) |0/36 (0%) 0/34 (0%) 1/31 (3%) 1/29 (3%) |
|FIRST INCIDENCE | --- --- --- --- |553 715 609 735 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.510 P=0.757N P=0.462 P=0.726 |
|POLY 3 | (e) (e) (e) (e) |P=0.525 P=0.760 P=0.465 P=0.739 |
|POLY 1.5 | (e) (e) (e) (e) |P=0.541 P=0.759 P=0.476 P=0.746 |
|POLY 6 | (e) (e) (e) (e) |P=0.508 P=0.760N P=0.455 P=0.731 |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.572 P=0.755N P=0.546 P=0.755N |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.562 P=0.753N P=0.500 P=0.747 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 30
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Pancreas: Duct |
| Cyst |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/49 (0%) 0/47 (0%) |0/50 (0%) 2/50 (4%) 2/50 (4%) 0/49 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |0.0% 4.4% 4.9% 0.0% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 0/34 (0%) 0/34 (0%) |0/36 (0%) 2/34 (6%) 1/31 (3%) 0/29 (0%) |
|FIRST INCIDENCE | --- --- --- --- |--- 735 (T) 659 --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.483N P=0.226 P=0.207 (e) |
|POLY 3 | (e) (e) (e) (e) |P=0.457N P=0.239 P=0.217 (e) |
|POLY 1.5 | (e) (e) (e) (e) |P=0.446N P=0.238 P=0.223 (e) |
|POLY 6 | (e) (e) (e) (e) |P=0.470N P=0.241 P=0.212 (e) |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.455N P=0.226 P=0.226 (e) |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.430N P=0.247 P=0.247 (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/48 (0%) 1/48 (2%) 1/47 (2%) 1/47 (2%) |16/46 (35%) 20/48 (42%) 20/50 (40%) 9/47 (19%) |
|POLY-3 ADJUSTED (b)| 0.0% 2.3% 2.5% 2.3% |37.5% 45.3% 46.6% 22.5% |
|TERMINAL (d) | 0/34 (0%) 1/36 (3%) 1/33 (3%) 1/34 (3%) |12/33 (36%) 15/34 (44%) 13/31 (42%) 8/29 (28%) |
|FIRST INCIDENCE | --- 733 (T) 733 (T) 733 (T) |645 659 553 505 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.404 P=0.511 P=0.494 P=0.500 |P=0.109N P=0.312 P=0.192 P=0.150N |
|POLY 3 | P=0.419 P=0.505 P=0.490 P=0.503 |P=0.055N P=0.301 P=0.260 P=0.105N |
|POLY 1.5 | P=0.414 P=0.503 P=0.491 P=0.500 |P=0.040N* P=0.295 P=0.287 P=0.090N |
|POLY 6 | P=0.423 P=0.507 P=0.488 P=0.506 |P=0.076N P=0.309 P=0.246 P=0.126N |
|LOGISTIC REGRESSION| (e) P=0.511 P=0.494 P=0.500 |P=0.055N P=0.316 P=0.251 P=0.108N |
|COCH-ARM / FISHERS | P=0.406 P=0.500 P=0.495 P=0.495 |P=0.028N* P=0.318 P=0.376 P=0.071N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 31
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Preputial Gland |
| Ectasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 3/49 (6%) 5/49 (10%) 5/48 (10%) | |
|POLY-3 ADJUSTED (b)| 11.4% 6.7% 11.7% 11.2% | |
|TERMINAL (d) | 5/35 (14%) 2/37 (5%) 4/34 (12%) 3/34 (9%) | |
|FIRST INCIDENCE | 733 (T) 715 645 659 | |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.381 P=0.322N P=0.611 P=0.618 | |
|POLY 3 | P=0.411 P=0.343N P=0.615 P=0.621N | |
|POLY 1.5 | P=0.406 P=0.349N P=0.617 P=0.629N | |
|POLY 6 | P=0.413 P=0.334N P=0.614 P=0.613N | |
|LOGISTIC REGRESSION| P=0.407 P=0.324N P=0.605 P=0.621N | |
|COCH-ARM / FISHERS | P=0.390 P=0.369N P=0.617 P=0.603 | |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Preputial Gland |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 3/49 (6%) 4/49 (8%) 9/48 (19%) | |
|POLY-3 ADJUSTED (b)| 6.8% 6.6% 9.2% 19.7% | |
|TERMINAL (d) | 3/35 (9%) 2/37 (5%) 1/34 (3%) 3/34 (9%) | |
|FIRST INCIDENCE | 733 (T) 617 609 555 | |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.018 * P=0.635N P=0.481 P=0.070 | |
|POLY 3 | P=0.017 * P=0.648N P=0.494 P=0.069 | |
|POLY 1.5 | P=0.016 * P=0.654N P=0.493 P=0.063 | |
|POLY 6 | P=0.019 * P=0.639N P=0.498 P=0.076 | |
|LOGISTIC REGRESSION| P=0.014 * P=0.657N P=0.488 P=0.051 | |
|COCH-ARM / FISHERS | P=0.015 * P=0.651 P=0.489 P=0.052 | |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 32
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Prostate |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/49 (0%) 1/49 (2%) 1/49 (2%) | |
|POLY-3 ADJUSTED (b)| 4.4% 0.0% 2.4% 2.2% | |
|TERMINAL (d) | 0/35 (0%) 0/37 (0%) 1/33 (3%) 0/34 (0%) | |
|FIRST INCIDENCE | 462 --- 733 (T) 555 | |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.580N P=0.235N P=0.512N P=0.495N | |
|POLY 3 | P=0.585N P=0.239N P=0.526N P=0.501N | |
|POLY 1.5 | P=0.583N P=0.239N P=0.517N P=0.501N | |
|POLY 6 | P=0.587N P=0.238N P=0.535N P=0.502N | |
|LOGISTIC REGRESSION| P=0.616 P=0.345N P=0.524N P=0.665N | |
|COCH-ARM / FISHERS | P=0.580N P=0.253N P=0.508N P=0.508N | |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin: Prepuce |
| Inflammation Chronic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 4/50 (8%) 3/50 (6%) 3/50 (6%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 4.5% 8.6% 6.8% 6.6% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/35 (3%) 2/38 (5%) 1/34 (3%) 0/34 (0%) |0/36 (0%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | 561 617 548 555 |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.527 P=0.373 P=0.487 P=0.499 |(e) (e) (e) (e) |
|POLY 3 | P=0.553 P=0.356 P=0.494 P=0.513 |(e) (e) (e) (e) |
|POLY 1.5 | P=0.553 P=0.352 P=0.498 P=0.511 |(e) (e) (e) (e) |
|POLY 6 | P=0.551 P=0.363 P=0.491 P=0.514 |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.531 P=0.322 P=0.496 P=0.464 |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.545 P=0.339 P=0.500 P=0.500 |(e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 33
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |0/50 (0%) 2/50 (4%) 2/50 (4%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |0.0% 4.2% 4.8% 0.0% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 0/34 (0%) 0/34 (0%) |0/36 (0%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | --- --- --- --- |--- 124 483 --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.434N P=0.240 P=0.220 (e) |
|POLY 3 | (e) (e) (e) (e) |P=0.453N P=0.249 P=0.221 (e) |
|POLY 1.5 | (e) (e) (e) (e) |P=0.440N P=0.246 P=0.226 (e) |
|POLY 6 | (e) (e) (e) (e) |P=0.466N P=0.251 P=0.218 (e) |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.467N P=0.304 P=0.302 (e) |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.424N P=0.247 P=0.247 (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Inflammation Chronic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) 0/50 (0%) |0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 4.7% 0.0% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 2/34 (6%) 0/34 (0%) |0/36 (0%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | --- --- 733 (T) --- |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.520 (e) P=0.232 (e) |(e) (e) (e) (e) |
|POLY 3 | P=0.544 (e) P=0.232 (e) |(e) (e) (e) (e) |
|POLY 1.5 | P=0.544 (e) P=0.235 (e) |(e) (e) (e) (e) |
|POLY 6 | P=0.542 (e) P=0.229 (e) |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| (e) (e) P=0.232 (e) |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.536 (e) P=0.247 (e) |(e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 34
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Spleen |
| Hematopoietic Cell Proliferation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 17/50 (34%) 13/50 (26%) 19/49 (39%) 18/47 (38%) |23/50 (46%) 22/50 (44%) 22/50 (44%) 28/49 (57%) |
|POLY-3 ADJUSTED (b)| 36.6% 27.2% 41.9% 39.3% |48.7% 46.5% 48.2% 62.4% |
|TERMINAL (d) | 8/35 (23%) 8/38 (21%) 11/34 (32%) 8/34 (24%) |15/36 (42%) 14/34 (41%) 11/31 (36%) 16/29 (55%) |
|FIRST INCIDENCE | 561 478 232 555 |533 533 281 412 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.231 P=0.213N P=0.383 P=0.498 |P=0.048 * P=0.538N P=0.432 P=0.081 |
|POLY 3 | P=0.208 P=0.224N P=0.380 P=0.479 |P=0.077 P=0.496N P=0.564N P=0.129 |
|POLY 1.5 | P=0.200 P=0.227N P=0.394 P=0.465 |P=0.096 P=0.505N P=0.539N P=0.151 |
|POLY 6 | P=0.215 P=0.228N P=0.363 P=0.488 |P=0.059 P=0.490N P=0.575 P=0.107 |
|LOGISTIC REGRESSION| P=0.158 P=0.280N P=0.388 P=0.380 |P=0.113 P=0.500N P=0.481N P=0.159 |
|COCH-ARM / FISHERS | P=0.177 P=0.257N P=0.388 P=0.409 |P=0.121 P=0.500N P=0.500N P=0.182 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Spleen |
| Hyperplasia Lymphoid |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 5/50 (10%) 3/49 (6%) 2/47 (4%) |20/50 (40%) 12/50 (24%) 18/50 (36%) 7/49 (14%) |
|POLY-3 ADJUSTED (b)| 2.3% 10.9% 7.1% 4.6% |43.6% 26.3% 43.0% 17.0% |
|TERMINAL (d) | 1/35 (3%) 4/38 (11%) 3/34 (9%) 1/34 (3%) |17/36 (47%) 10/34 (29%) 14/31 (45%) 7/29 (24%) |
|FIRST INCIDENCE | 733 (T) 715 733 (T) 723 |553 659 623 735 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.488N P=0.127 P=0.294 P=0.496 |P=0.067N P=0.087N P=0.517 P=0.015N* |
|POLY 3 | P=0.463N P=0.112 P=0.294 P=0.496 |P=0.034N* P=0.061N P=0.561N P=0.005N** |
|POLY 1.5 | P=0.468N P=0.110 P=0.297 P=0.492 |P=0.025N* P=0.064N P=0.516N P=0.004N** |
|POLY 6 | P=0.460N P=0.116 P=0.291 P=0.499 |P=0.047N* P=0.060N P=0.583 P=0.007N** |
|LOGISTIC REGRESSION| P=0.478N P=0.120 P=0.294 P=0.500 |P=0.040N* P=0.058N P=0.585N P=0.007N** |
|COCH-ARM / FISHERS | P=0.486N P=0.102 P=0.301 P=0.477 |P=0.019N* P=0.066N P=0.418N P=0.004N** |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 35
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Ulcer |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 0/49 (0%) 1/49 (2%) |1/49 (2%) 1/50 (2%) 0/50 (0%) 2/49 (4%) |
|POLY-3 ADJUSTED (b)| 4.5% 0.0% 0.0% 2.3% |2.2% 2.2% 0.0% 4.7% |
|TERMINAL (d) | 1/35 (3%) 0/38 (0%) 0/34 (0%) 1/34 (3%) |1/36 (3%) 0/34 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | 462 --- --- 733 (T) |735 (T) 715 --- 497 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.543N P=0.226N P=0.243N P=0.504N |P=0.335 P=0.757 P=0.530N P=0.463 |
|POLY 3 | P=0.546N P=0.231N P=0.248N P=0.502N |P=0.353 P=0.758N P=0.520N P=0.483 |
|POLY 1.5 | P=0.543N P=0.232N P=0.245N P=0.501N |P=0.361 P=0.759N P=0.513N P=0.489 |
|POLY 6 | P=0.550N P=0.229N P=0.251N P=0.502N |P=0.347 P=0.756N P=0.526N P=0.478 |
|LOGISTIC REGRESSION| P=0.558N P=0.286N P=0.252N P=0.550N |P=0.406 P=0.759N (e) P=0.693 |
|COCH-ARM / FISHERS | P=0.536N P=0.247N P=0.253N P=0.508N |P=0.372 P=0.747N P=0.495N P=0.500 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Stomach, Forestomach: Epithelium |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 2/50 (4%) 3/49 (6%) 3/49 (6%) |2/49 (4%) 6/50 (12%) 1/50 (2%) 2/49 (4%) |
|POLY-3 ADJUSTED (b)| 13.5% 4.4% 7.0% 6.7% |4.4% 13.0% 2.5% 4.8% |
|TERMINAL (d) | 4/35 (11%) 1/38 (3%) 2/34 (6%) 2/34 (6%) |1/36 (3%) 3/34 (9%) 1/31 (3%) 0/29 (0%) |
|FIRST INCIDENCE | 647 710 645 656 |617 533 735 (T) 595 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.355N P=0.113N P=0.269N P=0.253N |P=0.276N P=0.137 P=0.551N P=0.639 |
|POLY 3 | P=0.339N P=0.121N P=0.258N P=0.237N |P=0.242N P=0.139 P=0.537N P=0.666 |
|POLY 1.5 | P=0.337N P=0.124N P=0.254N P=0.239N |P=0.229N P=0.137 P=0.524N P=0.676 |
|POLY 6 | P=0.343N P=0.118N P=0.263N P=0.236N |P=0.256N P=0.142 P=0.550N P=0.656 |
|LOGISTIC REGRESSION| P=0.332N P=0.122N P=0.255N P=0.239N |P=0.203N P=0.148 P=0.506N P=0.657N |
|COCH-ARM / FISHERS | P=0.336N P=0.134N P=0.254N P=0.254N |P=0.206N P=0.141 P=0.492N P=0.691N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 36
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Stomach, Glandular |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 0/50 (0%) 0/49 (0%) 0/48 (0%) |0/49 (0%) 2/50 (4%) 0/50 (0%) 0/48 (0%) |
|POLY-3 ADJUSTED (b)| 0.0% 0.0% 0.0% 0.0% |0.0% 4.4% 0.0% 0.0% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 0/34 (0%) 0/34 (0%) |0/36 (0%) 1/34 (3%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | --- --- --- --- |--- 659 --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | (e) (e) (e) (e) |P=0.295N P=0.243 (e) (e) |
|POLY 3 | (e) (e) (e) (e) |P=0.284N P=0.241 (e) (e) |
|POLY 1.5 | (e) (e) (e) (e) |P=0.279N P=0.239 (e) (e) |
|POLY 6 | (e) (e) (e) (e) |P=0.288N P=0.243 (e) (e) |
|LOGISTIC REGRESSION| (e) (e) (e) (e) |P=0.271N P=0.243 (e) (e) |
|COCH-ARM / FISHERS | (e) (e) (e) (e) |P=0.267N P=0.253 (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Testes |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 9/50 (18%) 2/50 (4%) 2/50 (4%) | |
|POLY-3 ADJUSTED (b)| 13.5% 19.2% 4.7% 4.4% | |
|TERMINAL (d) | 4/35 (11%) 5/38 (13%) 2/34 (6%) 1/34 (3%) | |
|FIRST INCIDENCE | 561 581 733 (T) 723 | |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.024N* P=0.356 P=0.151N P=0.145N | |
|POLY 3 | P=0.017N* P=0.324 P=0.144N P=0.129N | |
|POLY 1.5 | P=0.016N* P=0.314 P=0.139N P=0.128N | |
|POLY 6 | P=0.018N* P=0.338 P=0.152N P=0.131N | |
|LOGISTIC REGRESSION| P=0.017N* P=0.292 P=0.138N P=0.129N | |
|COCH-ARM / FISHERS | P=0.017N* P=0.288 P=0.134N P=0.134N | |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 37
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 13/50 (26%) 7/50 (14%) 8/48 (17%) |10/50 (20%) 17/50 (34%) 14/50 (28%) 12/49 (24%) |
|POLY-3 ADJUSTED (b)| 25.0% 28.0% 16.3% 18.1% |22.3% 37.1% 34.5% 28.8% |
|TERMINAL (d) | 10/35 (29%) 11/38 (29%) 7/34 (21%) 7/34 (21%) |10/36 (28%) 13/34 (38%) 14/31 (45%) 9/28 (32%) |
|FIRST INCIDENCE | 702 581 733 (T) 716 |735 (T) 672 735 (T) 646 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.161N P=0.502 P=0.234N P=0.323N |P=0.321 P=0.067 P=0.112 P=0.194 |
|POLY 3 | P=0.132N P=0.466 P=0.230N P=0.296N |P=0.490 P=0.092 P=0.154 P=0.326 |
|POLY 1.5 | P=0.134N P=0.449 P=0.222N P=0.306N |P=0.536 P=0.087 P=0.181 P=0.350 |
|POLY 6 | P=0.134N P=0.486 P=0.240N P=0.289N |P=0.444 P=0.098 P=0.132 P=0.304 |
|LOGISTIC REGRESSION| P=0.134N P=0.473 P=0.244N P=0.286N |P=0.384 P=0.087 P=0.112 P=0.261 |
|COCH-ARM / FISHERS | P=0.145N P=0.408 P=0.218N P=0.341N |P=0.485N P=0.088 P=0.241 P=0.384 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Tooth |
| Malformation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/1 (100%) 2/3 (67%) 1/1 (100%) 1/1 (100%) |0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) |
|POLY-3 ADJUSTED (b)| 100.0% 80.1% 100.0% 100.0% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/1 (100%) 2/2 (100%) 1/1 (100%) 1/1 (100%) |0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 733 (T) 733 (T) 733 (T) 733 (T) |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=1.000N P=1.000N (e) (e) |(e) (e) (e) (e) |
|POLY 3 | P=0.719 P=0.895N (e) (e) |(e) (e) (e) (e) |
|POLY 1.5 | P=0.619 P=0.792N (e) (e) |(e) (e) (e) (e) |
|POLY 6 | P=0.934 P=0.997N (e) (e) |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=1.000N P=1.000N (e) (e) |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.562 P=0.750N (e) (e) |(e) (e) (e) (e) |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 38
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Urinary Bladder |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | 1/49 (2%) 0/50 (0%) 0/46 (0%) 2/46 (4%) |0/48 (0%) 0/48 (0%) 0/50 (0%) 0/48 (0%) |
|POLY-3 ADJUSTED (b)| 2.3% 0.0% 0.0% 4.6% |0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/35 (0%) 0/38 (0%) 0/33 (0%) 0/34 (0%) |0/36 (0%) 0/32 (0%) 0/31 (0%) 0/29 (0%) |
|FIRST INCIDENCE | 561 --- --- 555 |--- --- --- --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | P=0.208 P=0.500N P=0.509N P=0.502 |(e) (e) (e) (e) |
|POLY 3 | P=0.194 P=0.492N P=0.517N P=0.495 |(e) (e) (e) (e) |
|POLY 1.5 | P=0.194 P=0.493N P=0.514N P=0.491 |(e) (e) (e) (e) |
|POLY 6 | P=0.194 P=0.492N P=0.520N P=0.498 |(e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.126 P=0.571N P=0.567N P=0.377 |(e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.191 P=0.495N P=0.516N P=0.476 |(e) (e) (e) (e) |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Uterus |
| Angiectasis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | |1/49 (2%) 1/50 (2%) 2/50 (4%) 0/50 (0%) |
|POLY-3 ADJUSTED (b)| |2.2% 2.2% 4.9% 0.0% |
|TERMINAL (d) | |0/36 (0%) 1/34 (3%) 2/31 (7%) 0/29 (0%) |
|FIRST INCIDENCE | |533 735 (T) 735 (T) --- |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | |P=0.430N P=0.754 P=0.455 P=0.522N |
|POLY 3 | |P=0.405N P=0.760 P=0.461 P=0.515N |
|POLY 1.5 | |P=0.391N P=0.760 P=0.475 P=0.508N |
|POLY 6 | |P=0.420N P=0.760 P=0.449 P=0.523N |
|LOGISTIC REGRESSION| |P=0.366N P=0.729N P=0.537 P=0.329N |
|COCH-ARM / FISHERS | |P=0.370N P=0.747N P=0.508 P=0.495N |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 39
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Uterus |
| Hydrometra |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | |2/49 (4%) 4/50 (8%) 3/50 (6%) 4/50 (8%) |
|POLY-3 ADJUSTED (b)| |4.5% 8.8% 7.3% 9.4% |
|TERMINAL (d) | |2/36 (6%) 4/34 (12%) 2/31 (7%) 2/29 (7%) |
|FIRST INCIDENCE | |735 (T) 735 (T) 609 595 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | |P=0.270 P=0.310 P=0.435 P=0.255 |
|POLY 3 | |P=0.332 P=0.342 P=0.460 P=0.314 |
|POLY 1.5 | |P=0.349 P=0.340 P=0.474 P=0.325 |
|POLY 6 | |P=0.316 P=0.344 P=0.450 P=0.303 |
|LOGISTIC REGRESSION| |P=0.330 P=0.310 P=0.466 P=0.317 |
|COCH-ARM / FISHERS | |P=0.379 P=0.349 P=0.510 P=0.349 |
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Uterus |
| Hyperplasia Cystic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | |2/49 (4%) 2/50 (4%) 2/50 (4%) 3/50 (6%) |
|POLY-3 ADJUSTED (b)| |4.4% 4.4% 4.9% 7.1% |
|TERMINAL (d) | |1/36 (3%) 1/34 (3%) 1/31 (3%) 3/29 (10%) |
|FIRST INCIDENCE | |684 715 715 735 (T) |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | |P=0.292 P=0.686 P=0.635 P=0.410 |
|POLY 3 | |P=0.342 P=0.691N P=0.657 P=0.470 |
|POLY 1.5 | |P=0.360 P=0.692N P=0.671 P=0.484 |
|POLY 6 | |P=0.324 P=0.690N P=0.645 P=0.454 |
|LOGISTIC REGRESSION| |P=0.324 P=0.691N P=0.659 P=0.455 |
|COCH-ARM / FISHERS | |P=0.387 P=0.684N P=0.684N P=0.510 |
|=================================================================================================================================|
Date: 03/09/99 EXPERIMENT: 05180 TEST: 07 Page 40
Statistical Analysis of Non-neoplastic Lesions in Mice(B6C3F1) - GALLIUM ARSENIDE
Terminal Sacrifice at 105 weeks
|=================================================================================================================================|
| | | |
| | Males | Females |
|Dose | CONTROL 0.1 0.5 1.0 |CONTROL 0.1 0.5 1.0 |
| | MG/M3 MG/M3 MG/M3 | MG/M3 MG/M3 MG/M3 |
|=================================================================================================================================|
| |
|Uterus: Myometrium |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | | |
|----------- | | |
|OVERALL (a) | |2/49 (4%) 0/50 (0%) 2/50 (4%) 2/50 (4%) |
|POLY-3 ADJUSTED (b)| |4.5% 0.0% 4.9% 4.7% |
|TERMINAL (d) | |2/36 (6%) 0/34 (0%) 2/31 (7%) 0/29 (0%) |
|FIRST INCIDENCE | |735 (T) --- 735 (T) 628 |
|-------------------| | |
|STATISTICAL TESTS | | |
|-------------------| | |
|LIFE TABLE | |P=0.292 P=0.251N P=0.641 P=0.631 |
|POLY 3 | |P=0.331 P=0.235N P=0.658 P=0.675 |
|POLY 1.5 | |P=0.344 P=0.236N P=0.671 P=0.684 |
|POLY 6 | |P=0.320 P=0.233N P=0.647 P=0.667 |
|LOGISTIC REGRESSION| |P=0.329 (e) P=0.641 P=0.692 |
|COCH-ARM / FISHERS | |P=0.361 P=0.242N P=0.684N P=0.684N |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Poly-3 adjusted lifetime tumor incidence.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death.
Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fishers exact tests compare directly the overall incidence rates
For all tests a negative trend is indicated by N
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).